CYCART 201
Alternative Names: CYCART-201Latest Information Update: 25 Apr 2023
At a glance
- Originator Celularity
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 13 Apr 2023 Preclinical trials in Solid tumors in USA (Parenteral) (Celularity pipeline, April 2023)
- 11 Apr 2023 Preclinical trials in Mantle-cell lymphoma in USA (Parenteral) (Celularity pipeline, April 2023)
- 11 Apr 2023 Preclinical trials in Non-Hodgkin's lymphoma in USA (Parenteral) (Celularity pipeline, April 2023)